Stock Market Reviews

Read and share opinions on SLXN (Silexion Therapeutics Corp) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
  Sep 30, 2025
• Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
  Sep 25, 2025
• Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
  Sep 11, 2025
• Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
  Sep 4, 2025
• Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
  Sep 2, 2025
• Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
  Aug 12, 2025
• Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
  Aug 1, 2025
• Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
  Jul 31, 2025
• Silexion Therapeutics Announces 1-for-15 Reverse Share Split
  Jul 16, 2025
• Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
  Jul 9, 2025
• Silexion Therapeutics announces preclinical results on SIL204
  May 30, 2025
• Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers
  May 29, 2025
• Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer
  May 21, 2025
• Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
  May 13, 2025
• Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
  Apr 23, 2025
• Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
  Mar 28, 2025
• Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
  Mar 18, 2025